ABCB1 and neoplasm: They showed that combination therapy with siRNA targeting multidrug resistance protein 1 (MRP1) significantly enhanced DOX efficacy in vitro, and in vivo resulted in a substantial reduction in the tumor of tumors, which otherwise are nonresponsive to treatment with DOX.